Last reviewed · How we verify
Cetuximab,Paclitaxel,Cisplatin
Cetuximab,Paclitaxel,Cisplatin is a Small molecule drug developed by National Health Research Institutes, Taiwan. It is currently in Phase 2 development.
At a glance
| Generic name | Cetuximab,Paclitaxel,Cisplatin |
|---|---|
| Sponsor | National Health Research Institutes, Taiwan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fatigue
- Nausea
- Dysphagia
- Hypertension
- Odynophagia
- Weight loss
- Sore throat
- Constipation
- Oral pain
- Diarrhea
- Alopecia
- Neck pain
Key clinical trials
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer (PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (PHASE1)
- A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer (PHASE2)
- Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin (PHASE3)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cetuximab,Paclitaxel,Cisplatin CI brief — competitive landscape report
- Cetuximab,Paclitaxel,Cisplatin updates RSS · CI watch RSS
- National Health Research Institutes, Taiwan portfolio CI
Frequently asked questions about Cetuximab,Paclitaxel,Cisplatin
What is Cetuximab,Paclitaxel,Cisplatin?
Cetuximab,Paclitaxel,Cisplatin is a Small molecule drug developed by National Health Research Institutes, Taiwan.
Who makes Cetuximab,Paclitaxel,Cisplatin?
Cetuximab,Paclitaxel,Cisplatin is developed by National Health Research Institutes, Taiwan (see full National Health Research Institutes, Taiwan pipeline at /company/national-health-research-institutes-taiwan).
What development phase is Cetuximab,Paclitaxel,Cisplatin in?
Cetuximab,Paclitaxel,Cisplatin is in Phase 2.
What are the side effects of Cetuximab,Paclitaxel,Cisplatin?
Common side effects of Cetuximab,Paclitaxel,Cisplatin include Fatigue, Nausea, Dysphagia, Hypertension, Odynophagia, Weight loss.